BR9916363A - Composto, composição farmacêutica e método paratratar ou prevenir um distúrbio tromboembólico - Google Patents
Composto, composição farmacêutica e método paratratar ou prevenir um distúrbio tromboembólicoInfo
- Publication number
- BR9916363A BR9916363A BR9916363-2A BR9916363A BR9916363A BR 9916363 A BR9916363 A BR 9916363A BR 9916363 A BR9916363 A BR 9916363A BR 9916363 A BR9916363 A BR 9916363A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- pharmaceutical composition
- treat
- prevent
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000009424 thromboembolic effect Effects 0.000 title abstract 2
- 108010054265 Factor VIIa Proteins 0.000 abstract 2
- 108010074860 Factor Xa Proteins 0.000 abstract 2
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 abstract 2
- 229940012414 factor viia Drugs 0.000 abstract 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 abstract 1
- 108010022999 Serine Proteases Proteins 0.000 abstract 1
- 102000012479 Serine Proteases Human genes 0.000 abstract 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 abstract 1
- 239000003146 anticoagulant agent Substances 0.000 abstract 1
- 229940127219 anticoagulant drug Drugs 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000001041 indolyl group Chemical group 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 229960005356 urokinase Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/20—Two benzimidazolyl-2 radicals linked together directly or via a hydrocarbon or substituted hydrocarbon radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
Abstract
"COMPOSTO, COMPOSIçãO FARMACêUTICA E MéTODOPARA TRATAR OU PREVENIR UM DISTúRBIOTROMBOEMBóLICO" A presente invenção fornece novoscompostos da Fórmula (I): A-B. suas formas pró-medicamentos, ouseus sais farmaceuticamente aceitáveis, em que A representa umaestrutura de anel heterocíclico bicíclico saturado, insaturado ouparcialmente insaturado, e B representa um grupo arila ou umheteroarila. Compostos preferidos da presente invençãocompreendem um núcleo de benzimidazol ou de indol. Oscompostos desta invenção são inibidores das serina proteases,Urocinase (uPA), Fator Xa (FXa),e/ou Fator VIIa (FVIIa), e têmutilidade como agentes anti-câncer e/ou como anticoagulantespara o tratamento ou prevenção de distúrbios tromboembólicos emmamíferos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11300798P | 1998-12-18 | 1998-12-18 | |
PCT/US1999/030302 WO2000035886A2 (en) | 1998-12-18 | 1999-12-17 | (hetero)aryl-bicyclic heteroaryl derivatives, their preparation and their use as protease inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9916363A true BR9916363A (pt) | 2001-12-11 |
Family
ID=22347074
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9916363-2A BR9916363A (pt) | 1998-12-18 | 1999-12-17 | Composto, composição farmacêutica e método paratratar ou prevenir um distúrbio tromboembólico |
Country Status (20)
Country | Link |
---|---|
US (1) | US6867200B1 (pt) |
EP (1) | EP1140859A2 (pt) |
JP (1) | JP2002532479A (pt) |
KR (1) | KR20010086119A (pt) |
CN (1) | CN1344256A (pt) |
AU (1) | AU779117B2 (pt) |
BR (1) | BR9916363A (pt) |
CA (1) | CA2355249A1 (pt) |
CZ (1) | CZ20012006A3 (pt) |
EA (1) | EA200100675A1 (pt) |
EE (1) | EE200100323A (pt) |
HU (1) | HUP0104987A3 (pt) |
IL (1) | IL143801A0 (pt) |
NO (1) | NO20012980L (pt) |
NZ (1) | NZ512375A (pt) |
PL (1) | PL349192A1 (pt) |
SK (1) | SK7972001A3 (pt) |
TR (1) | TR200102533T2 (pt) |
UA (1) | UA70976C2 (pt) |
WO (1) | WO2000035886A2 (pt) |
Families Citing this family (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60128475T2 (de) * | 2000-07-25 | 2008-02-07 | Merck & Co., Inc. | N-substituierte indole mit anwendung in der behandlung von diabetes |
US6465503B2 (en) * | 2000-08-11 | 2002-10-15 | Axys Pharmaceuticals, Inc. | Selective urokinase inhibitors |
WO2002062829A1 (fr) | 2001-02-02 | 2002-08-15 | Chugai Seiyaku Kabushiki Kaisha | Derives de peptide |
SE0100902D0 (sv) | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
JP2004535411A (ja) | 2001-05-25 | 2004-11-25 | ブリストルーマイヤーズ スクイブ カンパニー | マトリックスメタロプロテナーゼ及び/またはTNF−α転換酵素(TACE)の阻害剤としてのヒダントイン及び関連複素環化合物 |
CA2452391A1 (en) * | 2001-07-09 | 2003-01-23 | Axys Pharmaceuticals, Inc. | 2-[5-(5-carbamimidoyl-1h-heteroaryl)-6-hydroxybiphenyl-3-yl]-succinic acid derivatives as factor viia inhibitors |
PL366799A1 (en) | 2001-07-27 | 2005-02-07 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
WO2003015715A2 (en) * | 2001-08-20 | 2003-02-27 | Bristol-Myers Squibb Company | Tetrahydroquinoline derivatives as antithrombotic agents |
SE0103710D0 (sv) | 2001-11-07 | 2001-11-07 | Astrazeneca Ab | Compounds |
EP1474400A1 (en) * | 2002-02-13 | 2004-11-10 | Axys Pharmaceuticals, Inc. | 2-[5-(5-carbamimidoyl-1h-heteroaryl)] -6-hydroxybiphenyl-3-yl derivatives as factor viia inhibitors |
US6867320B2 (en) | 2002-02-21 | 2005-03-15 | Asahi Kasei Pharma Corporation | Substituted phenylalkanoic acid derivatives and use thereof |
WO2003080545A2 (en) | 2002-03-20 | 2003-10-02 | Metabolex, Inc. | Substituted phenylacetic acids |
WO2004010996A1 (ja) * | 2002-07-29 | 2004-02-05 | Shizuoka Coffein Co., Ltd. | 1,3アゾール誘導体及び同誘導体を含む血栓症治療のための医薬組成物 |
SE0202539D0 (sv) * | 2002-08-27 | 2002-08-27 | Astrazeneca Ab | Compounds |
JP4377815B2 (ja) | 2002-08-29 | 2009-12-02 | メルク エンド カムパニー インコーポレーテッド | 抗糖尿病活性を有するインドール類 |
CN100513398C (zh) | 2002-12-03 | 2009-07-15 | Axys药物公司 | 作为因子viia抑制剂的2-(2-羟基联苯-3-基)-1h-苯并咪唑-5-甲脒衍生物 |
WO2004062661A1 (en) * | 2003-01-08 | 2004-07-29 | Axys Pharmaceuticals, Inc. | 2-‘5-(5-carbamimidoyl-1h-heteroaryl)-6-hydroxybiphenyl-3-yl!- carboxylic acid derivatives as factor viia inhibitors |
ES2295816T3 (es) | 2003-01-14 | 2008-04-16 | Arena Pharmaceuticals, Inc. | Derivados arilo y heteroarilo 1,2,3-trisustituidos como moduladores del metabolismo, y profilaxis y tratamiento de transtornos relacionados con los mismos, tales como la diabetes y la hiperglucemia. |
US7129264B2 (en) | 2003-04-16 | 2006-10-31 | Bristol-Myers Squibb Company | Biarylmethyl indolines and indoles as antithromboembolic agents |
US7199259B2 (en) | 2003-06-20 | 2007-04-03 | Metabolex, Inc. | Resolution of α-(phenoxy)phenylacetic acid derivatives |
AU2004265191A1 (en) | 2003-08-14 | 2005-02-24 | Asahi Kasei Pharma Corporation | Substituted arylalkanoic acid derivative and use thereof |
US7417063B2 (en) | 2004-04-13 | 2008-08-26 | Bristol-Myers Squibb Company | Bicyclic heterocycles useful as serine protease inhibitors |
CA2567437A1 (en) | 2004-05-25 | 2005-12-08 | Metabolex, Inc. | Substituted triazoles as modulators of ppar and methods of their preparation |
US8729117B2 (en) | 2004-06-02 | 2014-05-20 | Pharmacyclics, Inc. | Factor VIIa inhibitor |
KR100977903B1 (ko) * | 2004-06-02 | 2010-08-24 | 파마시클릭스, 인코포레이티드 | Ⅶa 인자 억제제 |
EP1751114A2 (en) * | 2004-06-02 | 2007-02-14 | Pharmacyclics, Inc. | Factor viia inhibitor |
US7648992B2 (en) | 2004-07-05 | 2010-01-19 | Astrazeneca Ab | Hydantoin derivatives for the treatment of obstructive airway diseases |
US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
US8048909B2 (en) * | 2004-09-30 | 2011-11-01 | Takeda Pharmaceutical Company Limited | Proton pump inhibitors |
SE0403085D0 (sv) | 2004-12-17 | 2004-12-17 | Astrazeneca Ab | Novel componds |
SE0403086D0 (sv) | 2004-12-17 | 2004-12-17 | Astrazeneca Ab | Compounds |
US7714131B2 (en) | 2005-09-23 | 2010-05-11 | Metabolex, Inc. | Process for the stereoselective preparation of (−)-halofenate and derivatives thereof |
AU2006311914C1 (en) * | 2005-11-03 | 2013-10-24 | Chembridge Corporation | Heterocyclic compounds as tyrosine kinase modulators |
WO2007114213A1 (ja) | 2006-03-30 | 2007-10-11 | Asahi Kasei Pharma Corporation | 置換二環式環状誘導体及びその用途 |
ES2422603T3 (es) | 2007-05-31 | 2013-09-12 | Shionogi & Co | Compuestos oxiimino y el uso de estos |
US20100215837A1 (en) * | 2007-06-19 | 2010-08-26 | Rhodri Evans | Process for making an electrode, an electrode and a battery comprising the electrode |
EP2586794A3 (en) | 2007-10-16 | 2013-07-17 | Pharmacyclics, Inc. | Manufacture, Compositions and Uses of Coagulationfactor VIIA Modulator |
JP5198560B2 (ja) | 2008-04-28 | 2013-05-15 | 旭化成ファーマ株式会社 | フェニルプロピオン酸誘導体及びその用途 |
EP2346820B1 (en) | 2008-06-11 | 2013-02-13 | Shionogi & Co., Ltd. | Oxycarbamoyl compounds and the use thereof |
AR072297A1 (es) | 2008-06-27 | 2010-08-18 | Novartis Ag | Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona. |
CN101654427B (zh) * | 2008-08-19 | 2012-12-05 | 信谊药厂 | 抗凝化合物、组合物及其用途 |
KR101354418B1 (ko) * | 2009-07-30 | 2014-01-23 | 단국대학교 산학협력단 | 형광 탐지자 및 이의 제조 방법 |
WO2012040279A1 (en) | 2010-09-22 | 2012-03-29 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
TWI501967B (zh) | 2010-12-16 | 2015-10-01 | Janssen R&D Ireland | 作為呼吸道融合病毒抗病毒劑之氮雜吲哚類 |
TWI527814B (zh) | 2010-12-16 | 2016-04-01 | 健生科學愛爾蘭無限公司 | 作為呼吸道融合病毒抗病毒劑之氮雜苯并咪唑類 |
TWI515187B (zh) | 2010-12-16 | 2016-01-01 | 健生科學愛爾蘭無限公司 | 作為呼吸道融合病毒抗病毒劑之吲哚類 |
TWI541241B (zh) * | 2010-12-16 | 2016-07-11 | 健生科學愛爾蘭無限公司 | 作為呼吸道融合病毒抗病毒劑之咪唑并吡啶類 |
CN103561573A (zh) * | 2011-04-26 | 2014-02-05 | 印第安纳大学研究与技术公司 | 酪氨酸磷酸酶及其在调节参与结核分枝杆菌之病理学的酶的活性中的用途 |
PT2864323T (pt) | 2012-06-15 | 2017-07-14 | Janssen Sciences Ireland Uc | Derivados de 1,3-di-hidro-2h-benzimidazol-2-ona substituídos com heterociclos como agentes antivirais do vírus sincicial respiratório |
EP2977374A1 (en) | 2014-07-21 | 2016-01-27 | Université de Strasbourg | Molecules presenting dual emission properties |
AU2015324313B2 (en) * | 2014-09-30 | 2018-11-15 | Transitions Optical, Inc. | Ultraviolet light absorbers |
NZ734220A (en) | 2015-01-06 | 2022-01-28 | Arena Pharm Inc | Methods of treating conditions related to the s1p1 receptor |
PE20180572A1 (es) | 2015-06-18 | 2018-04-04 | Cephalon Inc | Derivados de piperidina 1,4-sustituidos |
ES2849951T3 (es) | 2015-06-18 | 2021-08-24 | 89Bio Ltd | Derivados de piperidina 4-bencil y 4-benzoil sustituidos |
MA42807A (fr) | 2015-06-22 | 2018-07-25 | Arena Pharm Inc | Sel l-arginine cristallin d'acide (r)-2-(7-(4-cyclopentyl-3-(trifluorométhyl)benzyloxy)-1,2,3,4-tétrahydrocyclo-penta[b]indol-3-yl)acétique (composé 1) pour une utilisation dans des troubles associés au récepteur de s1p1 |
TW201718581A (zh) | 2015-10-19 | 2017-06-01 | 英塞特公司 | 作為免疫調節劑之雜環化合物 |
KR102547771B1 (ko) * | 2015-11-09 | 2023-06-26 | 고려대학교 산학협력단 | 4-치환된-2-(5-치환된-1h-인돌-2-일)페놀 유도체, 그 제조방법 및 이를 포함하는 세포 증식 및 전이 억제용 약학 조성물 |
ES2928856T3 (es) | 2015-11-19 | 2022-11-23 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
UA126113C2 (uk) | 2015-12-22 | 2022-08-17 | Інсайт Корпорейшн | Гетероциклічні сполуки як імуномодулятори |
WO2017192961A1 (en) * | 2016-05-06 | 2017-11-09 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
EP3464279B1 (en) | 2016-05-26 | 2021-11-24 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
CN105884673B (zh) * | 2016-06-03 | 2018-05-11 | 温州大学 | 一种吲哚衍生物的合成方法 |
WO2017222976A1 (en) | 2016-06-20 | 2017-12-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US10071079B2 (en) | 2016-06-29 | 2018-09-11 | Bristol-Myers Squibb Company | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds |
WO2018013789A1 (en) | 2016-07-14 | 2018-01-18 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
CA3031675A1 (en) | 2016-07-30 | 2018-02-08 | Bristol-Myers Squibb Company | Dimethoxyphenyl substituted indole compounds as tlr7, tlr8 or tlr9 inhibitors |
MA46045A (fr) | 2016-08-29 | 2021-04-28 | Incyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
KR102519535B1 (ko) | 2016-09-09 | 2023-04-06 | 브리스톨-마이어스 스큅 컴퍼니 | 피리딜 치환된 인돌 화합물 |
ES2874756T3 (es) | 2016-12-22 | 2021-11-05 | Incyte Corp | Derivados de triazolo[1,5-A]piridina como inmunomoduladores |
BR112019012957A2 (pt) | 2016-12-22 | 2019-11-26 | Incyte Corp | derivados de tetra-hidroimidazo[4,5-c]piridina como indutores de internalização de pd-l1 |
US20180179179A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
AU2017382870B2 (en) | 2016-12-22 | 2022-03-24 | Incyte Corporation | Benzooxazole derivatives as immunomodulators |
KR20190116416A (ko) | 2017-02-16 | 2019-10-14 | 아레나 파마슈티칼스, 인크. | 원발 담즙성 담관염을 치료하기 위한 화합물 및 방법 |
US11130756B2 (en) | 2017-08-04 | 2021-09-28 | Bristol-Myers Squibb Company | [1,2,4]Triazolo[4,3-A]pyridinyl substituted indole compounds |
KR102651947B1 (ko) | 2017-08-04 | 2024-03-26 | 브리스톨-마이어스 스큅 컴퍼니 | Tlr7/8/9의 억제제로서 유용한 치환된 인돌 화합물 |
JP7265554B2 (ja) | 2017-11-14 | 2023-04-26 | ブリストル-マイヤーズ スクイブ カンパニー | 置換インドール化合物 |
CN111819176B (zh) | 2017-12-18 | 2023-12-15 | 百时美施贵宝公司 | 4-氮杂吲哚化合物 |
AU2018390543A1 (en) | 2017-12-19 | 2020-08-06 | Bristol-Myers Squibb Company | 6-azaindole compounds |
WO2019126113A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Substituted indole compounds useful as tlr inhibitors |
MX2020005515A (es) | 2017-12-19 | 2020-09-03 | Bristol Myers Squibb Co | Compuestos de indol sustituidos con amida, utiles como inhibidores de receptores de tipo toll (tlr). |
AU2018390544A1 (en) | 2017-12-20 | 2020-08-06 | Bristol-Myers Squibb Company | Diazaindole compounds |
CA3085942A1 (en) | 2017-12-20 | 2019-06-27 | Bristol-Myers Squibb Company | Aryl and heteroaryl substituted indole compounds |
CA3086431A1 (en) | 2017-12-20 | 2019-06-27 | Bristol-Myers Squibb Company | Amino indole compounds useful as tlr inhibitors |
SI3774791T1 (sl) | 2018-03-30 | 2023-04-28 | Incyte Corporation | Heterociklične spojine kot imunomodulatorji |
DK3790877T3 (da) | 2018-05-11 | 2023-04-24 | Incyte Corp | Tetrahydro-imidazo[4,5-c]pyridinderivater som pd-l1-immunmodulatorer |
ES2963696T3 (es) | 2018-10-24 | 2024-04-01 | Bristol Myers Squibb Co | Compuestos diméricos de indol sustituidos |
CA3150434A1 (en) | 2019-08-09 | 2021-02-18 | Incyte Corporation | Salts of a pd-1/pd-l1 inhibitor |
BR112022005826A2 (pt) | 2019-09-30 | 2022-06-21 | Incyte Corp | Compostos de pirido[3,2-d]pirimidina como imunomoduladores |
MX2022005651A (es) | 2019-11-11 | 2022-07-27 | Incyte Corp | Sales y formas cristalinas de un inhibidor de la proteina de muerte celular programada 1 (pd-1)/ligando de muerte celular programada 1 (pd-l1). |
WO2022099018A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Process of preparing a pd-1/pd-l1 inhibitor |
US11760756B2 (en) | 2020-11-06 | 2023-09-19 | Incyte Corporation | Crystalline form of a PD-1/PD-L1 inhibitor |
JP2023548859A (ja) | 2020-11-06 | 2023-11-21 | インサイト・コーポレイション | Pd-1/pd-l1阻害剤ならびにその塩及び結晶形態を作製するためのプロセス |
CN117430525A (zh) * | 2023-03-01 | 2024-01-23 | 中化学科学技术研究有限公司 | 席夫碱配体及其制备方法和应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3224512A1 (de) | 1982-07-01 | 1984-01-05 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue imidazolderivate, ihre herstellung und diese verbindungen enthaltende arzneimittel |
JPS63166588A (ja) * | 1986-12-27 | 1988-07-09 | Kanzaki Paper Mfg Co Ltd | クロメノ化合物およびクロメノ化合物を用いた感熱記録体 |
JP2869561B2 (ja) * | 1989-05-22 | 1999-03-10 | 大塚製薬株式会社 | 血小板粘着抑制剤 |
US6255091B1 (en) * | 1995-04-28 | 2001-07-03 | Axys Pharmaceuticals, Inc. | Potentiating metal mediated serine protease inhibitors with cobalt or zinc ions |
WO1999026933A1 (en) | 1997-11-26 | 1999-06-03 | Axys Pharmaceuticals, Inc. | Substituted amidinoaryl derivatives and their use as anticoagulants |
US6150379A (en) | 1997-11-26 | 2000-11-21 | Axys Pharmaceuticals, Inc. | Compounds and compositions as anticoagulants |
-
1999
- 1999-12-17 PL PL99349192A patent/PL349192A1/xx not_active Application Discontinuation
- 1999-12-17 BR BR9916363-2A patent/BR9916363A/pt not_active IP Right Cessation
- 1999-12-17 EE EEP200100323A patent/EE200100323A/xx unknown
- 1999-12-17 US US09/868,276 patent/US6867200B1/en not_active Expired - Lifetime
- 1999-12-17 JP JP2000588148A patent/JP2002532479A/ja active Pending
- 1999-12-17 UA UA2001064172A patent/UA70976C2/uk unknown
- 1999-12-17 CZ CZ20012006A patent/CZ20012006A3/cs unknown
- 1999-12-17 CN CN99814722A patent/CN1344256A/zh active Pending
- 1999-12-17 CA CA002355249A patent/CA2355249A1/en not_active Abandoned
- 1999-12-17 KR KR1020017007688A patent/KR20010086119A/ko not_active Application Discontinuation
- 1999-12-17 AU AU27115/00A patent/AU779117B2/en not_active Ceased
- 1999-12-17 EA EA200100675A patent/EA200100675A1/ru unknown
- 1999-12-17 IL IL14380199A patent/IL143801A0/xx unknown
- 1999-12-17 NZ NZ512375A patent/NZ512375A/en unknown
- 1999-12-17 TR TR2001/02533T patent/TR200102533T2/xx unknown
- 1999-12-17 HU HU0104987A patent/HUP0104987A3/hu unknown
- 1999-12-17 EP EP99968917A patent/EP1140859A2/en not_active Withdrawn
- 1999-12-17 SK SK797-2001A patent/SK7972001A3/sk unknown
- 1999-12-17 WO PCT/US1999/030302 patent/WO2000035886A2/en not_active Application Discontinuation
-
2001
- 2001-06-15 NO NO20012980A patent/NO20012980L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
UA70976C2 (uk) | 2004-11-15 |
EE200100323A (et) | 2002-08-15 |
EP1140859A2 (en) | 2001-10-10 |
WO2000035886A2 (en) | 2000-06-22 |
US6867200B1 (en) | 2005-03-15 |
CA2355249A1 (en) | 2000-06-22 |
CZ20012006A3 (cs) | 2002-03-13 |
HUP0104987A3 (en) | 2002-09-30 |
NO20012980L (no) | 2001-08-01 |
HUP0104987A2 (hu) | 2002-07-29 |
EA200100675A1 (ru) | 2001-12-24 |
KR20010086119A (ko) | 2001-09-07 |
SK7972001A3 (en) | 2002-06-04 |
IL143801A0 (en) | 2002-04-21 |
AU2711500A (en) | 2000-07-03 |
JP2002532479A (ja) | 2002-10-02 |
NO20012980D0 (no) | 2001-06-15 |
NZ512375A (en) | 2003-11-28 |
CN1344256A (zh) | 2002-04-10 |
AU779117B2 (en) | 2005-01-06 |
PL349192A1 (en) | 2002-07-01 |
TR200102533T2 (tr) | 2006-06-21 |
WO2000035886A3 (en) | 2000-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9916363A (pt) | Composto, composição farmacêutica e método paratratar ou prevenir um distúrbio tromboembólico | |
DE60132975D1 (de) | Neue substanzen und verbindungen als protease-inhibitoren | |
TR200001279T2 (tr) | Poli (ADP-riboz) polimeraz ("PARP") inhibitörleri, nevral ve kardiyovasküler doku hasarının tedavisi için yöntemler ve farmasötik bileşimler. | |
NO990433L (no) | Nye forbindelser og blandinger for behandling av sykdommer i forbindelse med tryptase-aktivitet | |
NO20060974L (no) | Pyridazinderivater og deres anvendelse som terapeutiske midler | |
DE60324183D1 (en) | Aryl-, aryloxy- und alkyloxysubstituierte 1h-indol-3-yl-glyoxylsäurederivateals inhibitoren des plasminogenaktivatorinhibitors-1 (pai-1) | |
BR0009167A (pt) | Inibidores de enzima impdh | |
GEP20022676B (en) | 4-Phenyl-Pyridine Derivatives, Method for Their Production and Their Use for Treatment of Disorders Caused by Antagonist of NK-1 Receptors | |
EE200100487A (et) | Uudsed ühendid ja kompositsioonid proteaasiinhibiitoritena | |
TR200201505T2 (tr) | Terapötik maddeler olarak pirazolopirimidinler | |
ECSP045115A (es) | INDOL-2-CARBOXAMIDAS COMO INHIBIDORES DEL FACTOR Xa | |
BR9810841A (pt) | Inibidores de metaloprotease alicìclicos | |
BR0007424A (pt) | Composto, composição farmacêutica, método para o tratamento de depressão em um paciente necessitando do mesmo, e, processo para a preparação de um composto | |
NO20014529D0 (no) | Tetrahydropyranderivater og deres anvendelse som terapautiske midler | |
ES2136252T3 (es) | Tratamiento de enfermedades causadas por trastornos de la glandula sebacea mediante el uso de inhibidores de acil coa colesterol acil transferasa. | |
ID24228A (id) | (+)norcisaprida yang berguna untuk gangguan tertular 5-ht3 dan 5-ht4 | |
DK1458393T3 (da) | Substituerede diketopiperaziner som oxytocinantagonister | |
NO20050279D0 (no) | Ny fremgangsmate | |
ATE342264T1 (de) | Indolderivate und deren verwendung als gnrh antagonisten | |
DK1226819T3 (da) | Inhibitor for 20-HETE-producerende enzym | |
SE0002353D0 (sv) | New use | |
ATE293602T1 (de) | 2-aminopyridine als inhibitoren von cyclooxygenase-2 | |
DE69910706D1 (de) | Medikament zur Behandlung von Glaukoma und ischämischer Retinopathie | |
DK1343523T3 (da) | Anvendelse af aktiveret faktor VII til behandling af thrombolytisk terapi-inducerede alvorlige blödninger | |
BR0211847A (pt) | Composto ou um derivado farmaceuticamente aceitável do mesmo, formulação farmacêutica, uso do composto ou do derivado, métodos para tratar uma condição onde a inibição de trombina é requerida, e para tratar uma condição onde a terapia anticoagulante é indicada, e, processo para a preparação de um composto |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A E 8A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1962 DE 12/08/2008. |